Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Christos Chouaid

Showing results (71-80 of 209) with videos related to

Pageof 21
Sort By:
Bulletin Du Cancer|December 31, 2024
Epidemiology of metastatic lung cancer in France between 2013 and 2021: Observational study using the French claims databaseChristos Chouaid, Clarisse Marchal, Marion Apert, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|December 15, 2010
Cost-effectiveness of second-line chemotherapy for non-small cell lung cancer: an economic, randomized, prospective, multicenter phase III trial comparing docetaxel and pemetrexed: the GFPC 05-06 studyAlain Vergnenegre, Romain Corre, Henri Berard, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|July 29, 2017
Cost-Effectiveness Analysis of Afatinib versus Gefitinib for First-Line Treatment of Advanced EGFR-Mutated Advanced Non-Small Cell Lung CancersChristos Chouaid, Laura Luciani, Katell LeLay, et al.
Lung Cancer (Amsterdam, Netherlands)|August 19, 2019
Erratum to "Intracerebral efficacy and tolerance of nivolumab in non-small-cell lung cancer patients with brain metastases" [Lung Cancer 116 (February 2018) 62-66]Clément Gauvain, Enora Vauléon, Christos Chouaid, et al.
Cancer Medicine|February 27, 2018
Determinants of malignant pleural mesothelioma survival and burden of disease in France: a national cohort analysisChristos Chouaid, Jean Baptiste Assié, Pascal Andujar, et al.
Future Oncology (London, England)|May 1, 2020
Treatment sequence of first and second generation tyrosine kinase inhibitor followed by osimertinib in <i>EGFR</i>-mutated non-small-cell lung cancer: a real life studyNicolas Girard, Denis Moro-Sibilot, Stéphane Bouée, et al.
Chest|November 9, 2007
A web-based Delphi study on the indications of chest radiographs for patients in ICUsGilles Hejblum, Vincent Ioos, Jean-François Vibert, et al.
Cell Death & Disease|February 7, 2018
Beclin1 circulating levels and accelerated aging markers in COPDFrédéric Schlemmer, Laurent Boyer, Thibaud Soumagne, et al.
Lung Cancer (Amsterdam, Netherlands)|December 14, 2011
A cross-market cost comparison of erlotinib versus pemetrexed for first-line maintenance treatment of patients with locally advanced or metastatic non-small-cell lung cancerMark J C Nuijten, Javier de Castro Carpeño, Christos Chouaid, et al.
Expert Review of Anticancer Therapy|July 12, 2018
Immune-checkpoint inhibitors to treat cancers in specific immunocompromised populations: a critical reviewHélène Babey, Gilles Quéré, Renaud Descourt, et al.
Pageof 21

Showing results (71-80 of 209) with videos related to

Sort By:
Pageof 21
Bulletin Du Cancer|December 31, 2024
Epidemiology of metastatic lung cancer in France between 2013 and 2021: Observational study using the French claims databaseChristos Chouaid, Clarisse Marchal, Marion Apert, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|December 15, 2010
Cost-effectiveness of second-line chemotherapy for non-small cell lung cancer: an economic, randomized, prospective, multicenter phase III trial comparing docetaxel and pemetrexed: the GFPC 05-06 studyAlain Vergnenegre, Romain Corre, Henri Berard, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|July 29, 2017
Cost-Effectiveness Analysis of Afatinib versus Gefitinib for First-Line Treatment of Advanced EGFR-Mutated Advanced Non-Small Cell Lung CancersChristos Chouaid, Laura Luciani, Katell LeLay, et al.
Lung Cancer (Amsterdam, Netherlands)|August 19, 2019
Erratum to "Intracerebral efficacy and tolerance of nivolumab in non-small-cell lung cancer patients with brain metastases" [Lung Cancer 116 (February 2018) 62-66]Clément Gauvain, Enora Vauléon, Christos Chouaid, et al.
Cancer Medicine|February 27, 2018
Determinants of malignant pleural mesothelioma survival and burden of disease in France: a national cohort analysisChristos Chouaid, Jean Baptiste Assié, Pascal Andujar, et al.
Future Oncology (London, England)|May 1, 2020
Treatment sequence of first and second generation tyrosine kinase inhibitor followed by osimertinib in <i>EGFR</i>-mutated non-small-cell lung cancer: a real life studyNicolas Girard, Denis Moro-Sibilot, Stéphane Bouée, et al.
Chest|November 9, 2007
A web-based Delphi study on the indications of chest radiographs for patients in ICUsGilles Hejblum, Vincent Ioos, Jean-François Vibert, et al.
Cell Death & Disease|February 7, 2018
Beclin1 circulating levels and accelerated aging markers in COPDFrédéric Schlemmer, Laurent Boyer, Thibaud Soumagne, et al.
Lung Cancer (Amsterdam, Netherlands)|December 14, 2011
A cross-market cost comparison of erlotinib versus pemetrexed for first-line maintenance treatment of patients with locally advanced or metastatic non-small-cell lung cancerMark J C Nuijten, Javier de Castro Carpeño, Christos Chouaid, et al.
Expert Review of Anticancer Therapy|July 12, 2018
Immune-checkpoint inhibitors to treat cancers in specific immunocompromised populations: a critical reviewHélène Babey, Gilles Quéré, Renaud Descourt, et al.
Pageof 21